Literature DB >> 24093080

Treatment of Alzheimer's Disease: Current Management and Experimental Therapeutics.

Lawrence S Honig1, Clara D Boyd.   

Abstract

Alzheimer's disease (AD) is a major cause of morbidity in the elderly. AD affects aver 5 million persons in the United States, but because it increases in incidence in the elderly, and the "graying" population, AD is projected to increase in prevalence by many-fold over the coming decades. AD causes progressive mental impairment, resulting in the inability of persons to care for themselves. As a consequence, AD results in enormous costs to society due to both lost productivity, and required care. Thus, improved management and treatment is essential. In this review we will briefly review current understanding of the disease, including roles of beta-amyloid and tau proteins. We will then discuss current therapies in use, including the evidence for treatments with supplements, established drugs, and investigational therapeutic strategies, recently completed and ongoing.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid; Anti-amyloid; Beta-amyloid; Beta-secretase; Cholinesterase; Dementia; Elderly; Experimental therapeutics; Gamma-secretase; Monoclonal antibody; Phosphotau; Secretase; Tau; Treatment

Year:  2013        PMID: 24093080      PMCID: PMC3786221          DOI: 10.1007/s13670-013-0056-3

Source DB:  PubMed          Journal:  Curr Transl Geriatr Exp Gerontol Rep        ISSN: 2162-4941


  64 in total

1.  Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.

Authors:  E R Siemers; J F Quinn; J Kaye; M R Farlow; A Porsteinsson; P Tariot; P Zoulnouni; J E Galvin; D M Holtzman; D S Knopman; J Satterwhite; C Gonzales; R A Dean; P C May
Journal:  Neurology       Date:  2006-02-28       Impact factor: 9.910

Review 2.  Case for and against specificity of depression in Alzheimer's disease.

Authors:  Christian Even; Daniel Weintraub
Journal:  Psychiatry Clin Neurosci       Date:  2010-06-21       Impact factor: 5.188

3.  Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.

Authors:  Vladimir Coric; Christopher H van Dyck; Stephen Salloway; Niels Andreasen; Mark Brody; Ralph W Richter; Hilkka Soininen; Stephen Thein; Thomas Shiovitz; Gary Pilcher; Susan Colby; Linda Rollin; Randy Dockens; Chahin Pachai; Erik Portelius; Ulf Andreasson; Kaj Blennow; Holly Soares; Charles Albright; Howard H Feldman; Robert M Berman
Journal:  Arch Neurol       Date:  2012-11

4.  A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease.

Authors:  Mark S Stein; Samuel C Scherer; Kylie S Ladd; Leonard C Harrison
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

5.  A phase II trial of huperzine A in mild to moderate Alzheimer disease.

Authors:  M S Rafii; S Walsh; J T Little; K Behan; B Reynolds; C Ward; S Jin; R Thomas; P S Aisen
Journal:  Neurology       Date:  2011-04-19       Impact factor: 9.910

6.  High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.

Authors:  Paul S Aisen; Lon S Schneider; Mary Sano; Ramon Diaz-Arrastia; Christopher H van Dyck; Myron F Weiner; Teodoro Bottiglieri; Shelia Jin; Karen T Stokes; Ronald G Thomas; Leon J Thal
Journal:  JAMA       Date:  2008-10-15       Impact factor: 56.272

Review 7.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

8.  Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial.

Authors:  Rob McCarney; Peter Fisher; Steve Iliffe; Robbert van Haselen; Mark Griffin; Jan van der Meulen; James Warner
Journal:  Int J Geriatr Psychiatry       Date:  2008-12       Impact factor: 3.485

Review 9.  Treatment strategies targeting amyloid β-protein.

Authors:  Dale Schenk; Guriqbal S Basi; Menelas N Pangalos
Journal:  Cold Spring Harb Perspect Med       Date:  2012-09-01       Impact factor: 6.915

10.  Trans-synaptic spread of tau pathology in vivo.

Authors:  Li Liu; Valerie Drouet; Jessica W Wu; Menno P Witter; Scott A Small; Catherine Clelland; Karen Duff
Journal:  PLoS One       Date:  2012-02-01       Impact factor: 3.240

View more
  3 in total

1.  Dietary interventions and cognition of Alzheimer's disease patients: a systematic review of randomized controlled trial.

Authors:  Sophia Camargos Moreira; Ann Kristine Jansen; Flávia Moraes Silva
Journal:  Dement Neuropsychol       Date:  2020 Jul-Sep

2.  Clozapine Improves Memory Impairment and Reduces Aβ Level in the Tg-APPswe/PS1dE9 Mouse Model of Alzheimer's Disease.

Authors:  Yura Choi; Ha Jin Jeong; Quan Feng Liu; Seung Tack Oh; Byung-Soo Koo; Yeni Kim; In-Won Chung; Yong Sik Kim; Songhee Jeon
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

3.  Geniposide, the component of the Chinese herbal formula Tongluojiunao, protects amyloid-β peptide (1-42-mediated death of hippocampal neurons via the non-classical estrogen signaling pathway.

Authors:  Jiao Li; Feng Wang; Haimin Ding; Chunyan Jin; Jinyan Chen; Yanan Zhao; Xiaojing Li; Wenju Chen; Ping Sun; Yan Tan; Qi Zhang; Xu Wang; Angran Fan; Qian Hua
Journal:  Neural Regen Res       Date:  2014-03-01       Impact factor: 5.135

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.